Doctor of Podiatric Medicine Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Joseph Albright

Podiatrist, Primary Podiatric Medicine Watsonville, CA Doctor of Podiatric Medicine

NPI 1568991073 CMS profile 11261065

47 Penny Ln Ste 1, Watsonville, CA 95076

Open in the dashboard

General payments

$2,290

40 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Albright of Watsonville, CA is reported in the CMS Open Payments database as having received $2,290 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Podiatrist, Primary Podiatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $311 8
2024 General $461 7
2023 General $180 4
2022 General $93 3
2021 General $1,244 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Albright
  • Podiatrist, Primary Podiatric Medicine median
  • Middle half of Podiatrist, Primary Podiatric Medicine
  • National median

In program year 2025, general payments to Joseph Albright were reported at $311. Among 368 Podiatrist, Primary Podiatric Medicine profiles paid that year, the median was $232 and the middle half received between $88 and $586.

Show as a table
Year Joseph Albright Podiatrist, Primary Podiatric Medicine median Middle half National median
2019 $0 $166 $51–$513 $163
2020 $0 $108 $33–$249 $114
2021 $1,244 $147 $52–$377 $132
2022 $93 $188 $66–$551 $149
2023 $180 $195 $70–$509 $160
2024 $461 $209 $59–$508 $164
2025 $311 $232 $88–$586 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Orthofix Medical, Inc. $747 10 payments
  2. Smith+Nephew, Inc. $447 8 payments
  3. Stryker Corporation $442 7 payments
  4. DePuy Synthes Sales Inc. $241 6 payments
  5. Alafair Biosciences,Inc. $177 2 payments
  6. Tactile Systems Technology Inc $92 1 payment
  7. Integra LifeSciences Corporation $57 2 payments
  8. Paragon 28, Inc. $27 1 payment
  9. Urgo Medical North America, LLC $25 1 payment
  10. ConvaTec Inc. $19 1 payment
  11. Other $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,651 33 payments
  2. Travel and Lodging $639 7 payments
Products named General payments · program years 2021–2025
  1. TrueLok $747 10 payments
  2. MOTOBAND $225 4 payments
  3. AUGMENT INJECTABLE $202 2 payments
  4. VersaWrap $177 2 payments
  5. HOFFMANN $134 2 payments
  6. TSF Ally $133 1 payment
  7. UNIUM $115 3 payments
  8. Cadence $113 1 payment
  9. Panta 2 $113 1 payment
  10. STRAVIX $94 2 payments
  11. Other $973 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

441

Median for Podiatry: 160

Drug cost

$3,360

Median for Podiatry: $2,368

Branded share of claims

8.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ciclopirox Generic 27 $1,047
Ketoconazole Generic 29 $577
Doxycycline Hyclate Generic 48 $423
Terbinafine Hcl Generic 36 $224
Mupirocin Generic 41 $214
Methylprednisolone Generic 33 $211
Cephalexin Generic 51 $178
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 23 $151
Meloxicam Generic 93 $143
Triamcinolone Acetonide Generic 19 $80

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 104 billing codes

Paid by Medicare

$364,578

Of which drugs: $108,348

Medicare patients

808

Average age 76

Services billed

4,860

443 women, 365 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Diabetes 43%
Chronic kidney disease 28%
Ischemic heart disease 21%
Heart failure 20%
Atrial fibrillation 20%
Depression 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 52 146 $110
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 50 198 $18

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Primary Podiatric Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record